Similarly, neoadjuvant trials of EGFR-TKIs in resectable NSCLC have typically employed 6–9 weeks of preoperative therapy, with MPR rates of 11%–25% and pCR rates of 0%–9%.29–32) These studies provide a valuable benchmark for comparison. This evidence concerns the gene EGFR and non-small cell lung carcinoma.